Effect of prior treatments on post-cdk 4/6 inhibitor survival in hormone receptor-positive breast cancer

HIGHLIGHTS

• who: Jeffrey Franks from the Department of Medicine, Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA have published the paper: Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancer, in the Journal: (JOURNAL)
• what: Together these studies emphasize the importance of This study shows the importance of prior treatment duration and class to the initiation of a CDK 4/6 inhibitors in women with HR+ HER2- MBC. In contrast, the study evaluated all combinations of CDK4/6 inhibitors in a substantially larger . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.